IQVIA Holdings Inc. (IQV) fair value analysis

S&P 500 · Updated 2026-09-07

IQVIA Holdings Inc. is a contract research organization that provides drug development, clinical trial management, and data analytics services to pharmaceutical, biotechnology, and medical device companies. The company operates globally with a presence across North America, Europe, Asia Pacific, and other international markets.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, IQV is trading at within about 10% of estimated fair value.

IQV currently ranks #69 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $267.77
Sector: Healthcare
12-month range: $157.77–$258.35

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: F
Leverage: High
Margin trend: Stable
Revenue growth: Modest
RSI zone: Overbought
52-week position: The top quarter of its range
DCF cross-check: Overvalued

What our data shows for IQV

Our model validated 17 trailing price-to-earnings windows for IQV, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $157.77–$258.35.
The 14-day relative strength index sits at an overbought 71.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for IQV
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent IQV news

TickrTrends' derived news-sentiment signal for IQV is currently leaning positive, computed from recent coverage.

IQVIA (IQV) Insider James Berkshire Sells 2,668 Shares (gurufocus.com, 2026-09-05)
TickrTrends take: IQVIA operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends analysis. Insider selling activity such as James Berkshire's recent disposition of 2,668 shares warrants monitoring alongside the company's fundamental metrics, particularly given the fair valuation designation which leaves limited margin for negative surprises. Investors tracking valuation shifts should observe whether such insider transactions accelerate or correlate with changes in the company's operational performance or market positioning in the contract research and data analytics space.
IQV Looks 9.6% Overvalued on GF Value™ as AI-Driven Clinical Innovation Unfolds (gurufocus.com, 2026-09-03)
TickrTrends take: IQVIA Holdings (IQV) operates in the Healthcare sector where valuation multiples can fluctuate based on clinical trial activity and AI adoption trends. The company's current TickrTrends verdict of Fairly valued contrasts with external valuation models suggesting downside risk, creating a discrepancy that valuation-focused investors should monitor as the company develops its AI-driven clinical innovation capabilities. Readers tracking IQV should watch for quarterly results that demonstrate whether the company's AI investments translate into revenue growth sufficient to justify current market pricing relative to peer valuations.

What people are saying

Follow the IQV conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — IQV's momentum indicator downgraded from A to none this week, signaling a loss of directional strength in the Healthcare sector stock. The relative strength index moved from neutral into overbought territory, suggesting the stock may have extended beyond sustainable levels. Despite these technical shifts, IQV remains assessed as fairly valued based on current fundamentals.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is IQV stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), IQV is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is IQV's TickrTrends verdict?

IQV's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does IQV compare to other Healthcare stocks?

IQV ranks #69 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is IQV overbought or oversold?

IQV's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.

All Healthcare fair-value coverage →

Head-to-head comparisons

IQV vs AZTA · IQV vs BAX · IQV vs ELV · IQV vs HSIC · IQV vs MDT